Doxefazepam
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| Image:Doxefazepam.svg | |
| Image:Doxefazepam3d.png | |
| Doxefazepam
| |
| Systematic (IUPAC) name | |
| 9-chloro-6-(2-fluorophenyl)-4-hydroxy -2-(2-hydroxyethyl)-2,5-diazabicyclo [5.4.0]undeca-5,8,10,12-tetraen-3-one | |
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H14ClFN2O3 |
| Mol. mass | 348.8 |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | Hepatic |
| Half life | ? |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
Schedule IV(US) |
| Routes | Oral |
Doxefazepam (marketed under brand name Doxans) is a drug which is a benzodiazepine derivative. It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties. According to Babbini and colleagues in 1975, this derivative of flurazepam was between 2 and 4 times more potent than the latter while at the same time being half as toxic in laboratory animals.[1]
Doxefazepam is not approved for sale in the United States or Canada.
